RxDoctor Payments Data

Florence Solages, MD

Endocrinology, Diabetes & Metabolism · Southwest Ranches, FLNPI 1598786485

Payments from drug & device makers

$2,324in general payments, 2019–2025

Across 93 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$492
  • Novo Nordisk$461
  • Lilly USA, LLC$412
  • Dexcom, Inc.$237
  • Boehringer Ingelheim$172
  • Corcept Therapeutics$93
  • plus $456 from 9 others

What the payments were for

  • Food & beverage$2,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,324 in reported general payments places this provider in the 40th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$9,674
Medicare patients
27
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin115$131,682
RybelsusSemaglutide90$124,515
OzempicSemaglutide59$56,752
MounjaroTirzepatide32$51,281
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp47$9,341
JanumetSitagliptin Phos/Metformin Hcl11$5,910
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$5,709
NovologInsulin Aspart15$4,229
Novolog FlexpenInsulin Aspart23$4,099
LantusInsulin Glargine,hum.Rec.Anlog15$3,555
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$964
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$920
Levothyroxine Sodium94$876
Glipizide83$372
Pioglitazone Hcl44$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic, Novolog$461$185,496164 claims
Boehringer IngelheimJardiance$172$131,682115 claims
Lilly USA, LLCMounjaro$412$51,28132 claims
MerckJanumet$49$5,91011 claims
Sanofi-aventis U.S. LLCLantus$62$3,55515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Southwest Ranches

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →